Sarcoma  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00996346: Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

Checkmark In combination with irinotecan for metastatic sarcoma
Nov 2013 - Nov 2013: In combination with irinotecan for metastatic sarcoma
Terminated
1/2
17
US
Irinotecan&Temsirolimus:Arm1, Level 1, Irinotecan = Camptosar, Campto, or CPT-11, Temsirolimus = Toricel or CCI-779, Irinotecan&Temsirolimus:Arm 1, Level 2, Irinotecan&Temsirolimus:Arm 2, Level 1
New Mexico Cancer Care Alliance, Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma
11/11
11/13
NCT00949325: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Temsirolimus+Liposomal doxorubicin
Feb 2013 - Feb 2013: Temsirolimus+Liposomal doxorubicin
Completed
1/2
24
US
temsirolimus plus liposomal doxorubicin, Torisel, Doxil
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Comprehensive Cancer Network, Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma
09/12
09/12
SARC023, NCT02008877: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Completed
1/2
20
US
ganetespib, STA-9090, Sirolimus, Rapamycin
Sarcoma Alliance for Research through Collaboration, Synta Pharmaceuticals Corp., United States Department of Defense
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
04/18
07/18

Download Options